S&P 500
7,548.20
-0.02%
Dow Jones
52,530.70
+0.03%
Nasdaq 100
29,738.60
-0.04%
Russell 2000
2,990.36
-0.01%
FTSE 100
10,480.00
-0.33%
Nikkei 225
68,877.20
-0.22%

Health and Healthcare

Another Bad Day For Boston Scientific (BSX)

Photo of Douglas A. McIntyre
By Douglas A. McIntyre Published
This post may contain links from our sponsors and affiliates, and Flywheel Publishing may receive compensation for actions taken through them.

The bad days never seem to end at Boston Scientific (NYSE: BSX). The company has a heavy debt load from a bad acquisition of Guidant. The BSX stent business has been hurt by studies that question the safety of the devices.

Now the company has been told by a court that it must pay $431 million to a doctor who holds patents on certain IP in BSX drug-coated stents. According to the AP, Boston Scientific "plans to try to overturn the verdict in post-trial motions. If that’s unsuccessful, Boston Scientific says it will appeal."

With the company’s luck that is not likely.

BSX shares trade just above $12, near their 52-week low and down from the period high of $17.32.

Douglas A. McIntyre

ro

Contact [email protected] for any questions or corrections.

DISCLOSURE:
INVESTMENTS ARE NOT FDIC INSURED • ARE NOT BANK GUARANTEED • MAY LOSE VALUE Brokerage and Active investing products offered through SoFi Securities LLC, member FINRA(www.finra.org)/SIPC(www.sipc.org). Advisory services are offered by SoFi Wealth LLC, an SEC-registered investment adviser. Information about SoFi Wealth’s advisory operations, services, and fees is set forth in SoFi Wealth’s current Form ADV Part 2 (Brochure), a copy of which is available upon request and at www.adviserinfo.sec.gov. Probability of Member receiving $1,000 is a probability of 0.026%; If you don’t make a selection in 30 days, you’ll no longer qualify for the promo. Customer must fund their account with a minimum of $50.00 to qualify. Other fees, such as exchange fees, may apply. Please view our fee disclosure to view a full listing of fees. Investing in alternative investments and/or strategies may not be suitable for all investors and involves unique risks, including the risk of loss. An investor should consider their individual circumstances and any investment information, such as a prospectus, prior to investing. Interval Funds are illiquid instruments, the ability to trade on your timeline may be restricted. Brokerage and Active investing products offered through SoFi Securities LLC, Member FINRA(www.finra.org) /SIPC(www.sipc.org). There are limitations with fractional shares to consider before investing. During market hours fractional share orders are transmitted immediately in the order received. There may be system delays from receipt of your order until execution and market conditions may adversely impact execution prices. Outside of market hours orders are received on a not held basis and will be aggregated for each security then executed in the morning trade window of the next business day at market open. Share will be delivered at an average price received for executing the securities through a single batched order. Fractional shares may not be transferred to another firm. Fractional shares will be sold when a transfer or closure request is initiated. Please consider that selling securities is a taxable event. Options involve risks, including substantial risk of loss and the possibility an investor may lose the entire investment Before trading options please review the Characteristics and Risks of Standardized Options  Investing in an Initial Public Offering (IPO) involves substantial risk, including the risk of loss. Further, there are a variety of risk factors to consider when investing in an IPO, including but not limited to, unproven management, significant debt, and lack of operating history. For a comprehensive discussion of these risks please refer to SoFi Securities’ IPO Risk Disclosure Statement This should not be considered a recommendation to participate in IPOs and investors should carefully read the offering prospectus to determine whether an offering is consistent with their investment objectives, risk tolerance, and financial situation. New offerings generally have high demand and there are a limited number of shares available for distribution to participants. Many customers may not be allocated shares and share allocations may be significantly smaller than the shares requested in the customer’s initial offer (Indication of Interest). For more information on the allocation process please visit IPO Allocation.
Follow 24/7 Wall St. on Google
Photo of Douglas A. McIntyre
About the Author Douglas A. McIntyre →

Douglas A. McIntyre is the co-founder, chief executive officer and editor in chief of 24/7 Wall St. and 24/7 Tempo. He has held these jobs since 2006.

McIntyre has written thousands of articles for 24/7 Wall St. He is an expert on corporate finance, the automotive industry, media companies and international finance. He has edited articles on national demographics, sports, personal income and travel.

His work has been quoted or mentioned in The New York Times, The Wall Street Journal, Los Angeles Times, The Washington Post, NBC News, Time, The New Yorker, HuffPost USA Today, Business Insider, Yahoo, AOL, MarketWatch, The Atlantic, Bloomberg, New York Post, Chicago Tribune, Forbes, The Guardian and many other major publications. McIntyre has been a guest on CNBC, the BBC and television and radio stations across the country.

A magna cum laude graduate of Harvard College, McIntyre also was president of The Harvard Advocate. Founded in 1866, the Advocate is the oldest college publication in the United States.

TheStreet.com, Comps.com and Edgar Online are some of the public companies for which McIntyre served on the board of directors. He was a Vicinity Corporation board member when the company was sold to Microsoft in 2002. He served on the audit committees of some of these companies.

McIntyre has been the CEO of FutureSource, a provider of trading terminals and news to commodities and futures traders. He was president of Switchboard, the online phone directory company. He served as chairman and CEO of On2 Technologies, the video compression company that provided video compression software for Adobe’s Flash. Google bought On2 in 2009.

Continue Reading

Douglas A. McIntyre |

No Signs Of Intelligent Life At Boston Scientific

Virtually nothing has gone right at Boston Scientific (BSX) since it bought rival Guidant in a bidding war with Johnson & Johnson (JNJ)…

Jon C. Ogg |

Boston Scientific’s New Stent May Assist in Turnaround (BSX, ABT, JNJ, MDT, STJ)

Boston Scientific Corporation (NYSE: BSX) has been a long and painful investment for thousands of shareholders who have held shares…

Douglas A. McIntyre |

A Reprieve For Boston Scientific (BSX)

Put back the crash carts. Boston Scientific is up and walking. A sharp decline in coated drug stents, brought on…

Douglas A. McIntyre |

Boston Scientific Begging For Good News

It’s always an interesting phenomenon when a large company becomes ultra-sensitive to news, as Boston Scientific (BSX) seems to be…

Douglas A. McIntyre |

New Class of Drug-Eluted Stents on the Horizon

by H.S. AyoubBioHealth Investor.com There have been many debates over the last couple of years as to the varying degree…

Douglas A. McIntyre |

The Below Average CEO: J. Raymond Elliott, Boston Scientific

Average: “an estimation of or approximation to an arithmetic mean”–Webster The smartest move that J. Raymond Elliot made in his…

Douglas A. McIntyre |

The Trouble Will Not End For Boston Scientific

Boston Scientific (BSX) has been vexed by problems with its stents, one of its largest businesses. There have been several…

Douglas A. McIntyre |

Cramer Has a Stent Trade

On tonight’s MAD MONEY show on CNBC, Cramer reviewed what the state of the stent market will be. There is…

Douglas A. McIntyre |

10 CEO’s That Need To Leave in 2008: James Tobin of Boston Scientific (BSX, BIIB, JNJ, ABT)

James Tobin, the CEO of Boston Scientific (NYSE:BSX) is likely to find himself in front of the shareholder firing squad…

Top Gaining Stocks

Hewlett Packard Enterprise
HPE • Vol: 26,398,547
Norwegian Cruise Line
NCLH • Vol: 17,598,302
Lam Research
LRCX • Vol: 12,109,308
Invesco
IVZ • Vol: 4,557,367
AMD
AMD • Vol: 26,866,096

Top Losing Stocks

Coterra Energy
CTRA • Vol: 73,319,495
APA
APA • Vol: 4,397,644
New Pluto Global
PSKY • Vol: 18,870,798
Costco
COST • Vol: 4,541,045
Cincinnati Financial
CINF • Vol: 2,196,176